eXmoor Pharma and Evox Therapeutics have completed the transfer of an exosome-enabled gene editing manufacturing process and its associated analytical methods to eXmoor’s Bristol facility.
The programme supports Evox’s MSH3-targeted treatment for Huntington’s disease, establishing the technical basis for a subsequent transition into good manufacturing practice production and future clinical manufacture.
Evox is developing gene editing medicines for genetically driven neurodegenerative diseases, including Huntington’s disease and amyotrophic lateral sclerosis. Its platform uses engineered exosomes to deliver therapeutic cargo to selected cells and tissues.
Exosomes are small membrane-bound vesicles that cells use naturally to transport biological material. Their potential as delivery vehicles has attracted substantial research interest, particularly where conventional viral vectors or synthetic systems face limitations involving tissue targeting, repeat dosing, payload, or immune response.
Transferring an exosome manufacturing process requires the receiving organisation to reproduce far more than a laboratory protocol. Raw materials, cell culture conditions, harvest timing, purification, filtration, storage, equipment differences, sampling, and operating ranges must all be understood before the process can be made repeatable.
The Bristol programme covered Evox’s proprietary production method and the analytical tests used to characterise the resulting material. Manufacturing cannot move into a regulated environment unless identity, purity, potency, and consistency can be demonstrated through methods that perform reliably at the receiving site.
Lucy Foley, chief executive officer of eXmoor Pharma, said the work required process development, analytical development, and manufacturing expertise to be integrated from the outset. Completion gives the partners a defined technical platform from which the next phase can proceed.
eXmoor operates as an integrated cell and gene therapy contract development and manufacturing organisation, combining process development, analytical services, regulatory support, facility design knowledge, and GMP manufacturing within its Bristol operation.
Advanced therapies confront industrial scale
Gene editing programmes can advance rapidly during discovery, while industrial development remains slower because a process producing enough material for laboratory studies may not deliver the yield, consistency, documentation, or contamination control required for human trials.
Exosome production adds further complexity because the delivery vehicle is generated through a biological system. Cell condition, culture parameters, harvest timing, purification, and storage can influence the properties of the final material, while relatively small changes may alter potency or introduce variation that a single analytical test cannot detect.
Scaling biological production involves more than moving the process into a larger vessel. Mixing, oxygen transfer, shear, temperature control, residence time, and downstream recovery can behave differently as equipment volume changes, requiring development teams to identify which parameters are critical to product quality.
Similar industrial constraints are shaping investment across the wider advanced therapy sector, where automated cell therapy manufacturing networks are being developed to improve throughput, repeatability, analytical release, and the economics of supplying complex medicines.
Contract development and manufacturing organisations are consequently becoming involved earlier, before a process has been fixed around laboratory equipment or materials that cannot support commercial scale. Delaying manufacturing decisions until clinical trials approach can force expensive redesign and lengthen the route into production.
Early process development also influences the cost of a potential therapy. Yield losses, lengthy purification, specialist consumables, manual handling, low equipment utilisation, and complex release testing can make a scientifically successful product difficult to manufacture at an acceptable price.
Delivery to the central nervous system presents an additional constraint for neurodegenerative treatments. Therapeutic material must reach relevant cells in sufficient quantity while limiting unwanted exposure elsewhere, connecting the control of the delivery vehicle directly with the biological performance of the medicine.
The completed transfer does not yet represent clinical production, since the process must progress through GMP transfer, qualification, validation, and the regulatory documentation required for trial manufacture. Raw material controls, facility procedures, employee training, and quality oversight must be incorporated into the technical process already established.
Moving the process successfully to its intended manufacturing site removes a substantial development risk, because the methods now exist outside the originating research environment. Equipment compatibility, operator practice, analytical performance, and documentation can be developed around the facility expected to produce future batches.
The next phase will establish whether the platform can retain its biological performance while meeting tighter controls for batch records, product release, contamination prevention, and capacity planning. Reproducible manufacture will determine whether exosome-enabled gene editing progresses from a promising delivery technology into a viable pharmaceutical process.
